Cardiopulmonary Stress Testing Systems Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cardiopulmonary stress testing systems market size has grown strongly in recent years. It will grow from $5.43 billion in 2024 to $5.8 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rise in cardiovascular and respiratory diseases, aging population, healthcare infrastructure development, awareness and prevention initiatives, reimbursement policies and healthcare spending.

The cardiopulmonary stress testing systems market size is expected to see strong growth in the next few years. It will grow to $7.17 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to personalized medicine and precision healthcare, remote patient monitoring and telemedicine, emphasis on preventive healthcare, population health management initiatives, expansion into emerging markets. Major trends in the forecast period include integration of wireless technology, adoption of portable and compact testing systems, advancements in software solutions, growing emphasis on preventive healthcare, expansion of telehealth and remote monitoring capabilities, integration of artificial intelligence, development of novel stress testing protocols.

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the cardiopulmonary stress testing systems market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels. The reasons for increasing prevalence of cardiovascular diseases include unhealthy diet, physical inactivity, and urbanization. Cardiopulmonary stress testing systems assess cardiovascular health by evaluating cardiac and pulmonary function during exercise. It provides valuable information for prescribing individualized exercise programs tailored to a patient's functional capacity and cardiovascular limitations. For instance, in June 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency of the United States, approximately 48% of adults in the United States have some form of cardiovascular disease, with around 12.5 million experiencing coronary artery disease (CAD) specifically. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the cardiopulmonary stress testing systems market.

Major companies in the cardiopulmonary stress testing system market are developing innovative products such as portable ECG to drive revenues in the market. Portable ECG refers to a device that can be used to record the electrical activity of the heart while on the go. For instance, in February 2022, AliveCor, a US-based medical device and AI company, launched the KardiaMobile Card, which is the world's first credit-card-sized personal ECG device. It is slim enough to fit into a wallet and delivers a medical-grade, single-lead ECG in 30 seconds. The device is FDA-cleared and can detect various heart conditions, including AFib, bradycardia, and tachycardia.

In May 2024, WearLinq, a US-based health technology company specializing in wearable devices for monitoring cardiac health, acquired AMI Cardiac Monitoring LLC for an undisclosed amount. This acquisition enhances WearLinq's capacity to deliver comprehensive clinical services nationwide and expand patient access to its eWave 6-lead wearable ECG monitor, which recently received FDA 510(k) clearance. AMI Cardiac Monitoring is a US-based healthcare technology company that provides advanced cardiac monitoring solutions. This acquisition is expected to strengthen WearLinq's position in the growing wearable health device market, particularly in the cardiac health sector.

Major companies operating in the cardiopulmonary stress testing systems market are Cardinal Health Inc., General Electric, Thermo Fisher Scientific Ltd., Siemens Healthineers AG, Becton Dickinson and Co., Koninklijke Philips N.V., GE Healthcare, Hill-rom Holdings Inc., Masimo Corporation, Halma plc, Nihon Kohden Corporation, OSI Systems Inc., Welch Allyn, Fukuda Denshi Co. Ltd., Spacelabs Healthcare, Schiller AG, Vyaire Medical Inc., Nonin Medical Inc., MGC Diagnostic Corporation, SunTech Medical Inc., COSMED srl, Allengers Medical Systems Ltd., Nasiff Associates Inc., CareFusion Corporation (BD), Clarity Medical.

North America was the largest region in the cardiopulmonary stress testing systems market in 2024. The regions covered in the cardiopulmonary stress testing systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiopulmonary stress testing systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiopulmonary stress testing systems market consists of sales of specialized systems, metabolic carts, and portable devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Cardiopulmonary stress testing systems are sophisticated diagnostic tools used in healthcare settings to evaluate the performance of the cardiovascular and respiratory systems under stress. These tests are valuable in designing individualized exercise prescriptions, assessing treatment effectiveness, and predicting prognosis in patients with cardiovascular and respiratory diseases.

The main product types of cardiopulmonary stress testing systems are cardiopulmonary exercise testing (CPET) systems, stress ECG, pulse oximeters, single-photon emission computed tomography (SPECT), and stress blood pressure monitors. Cardiopulmonary exercise testing (CPET) systems refer to a type of product used to evaluate the overall efficiency of a patient's cardiovascular and pulmonary systems. These are used in various applications such as oxygen uptake, carbon dioxide, minute ventilation, and anaerobic thresholds and also by various end users such as hospitals, specialty clinics/cardiology clinics, ambulatory surgical centers, and diagnostic centers.

The main product types of cardiopulmonary stress testing systems are cardiopulmonary exercise testing (CPET) systems, stress ECG, pulse oximeters, single-photon emission computed tomography (SPECT), and stress blood pressure monitors. Cardiopulmonary exercise testing (CPET) systems refer to a type of product used to evaluate the overall efficiency of a patient's cardiovascular and pulmonary systems. These are used in various applications such as oxygen uptake, carbon dioxide, minute ventilation, and anaerobic thresholds and also by various end users such as hospitals, specialty clinics/cardiology clinics, ambulatory surgical centers, and diagnostic centers.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.